Endocrinology
News
Dapagliflozin meets primary endpoint in the DAPA-HF trial
AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor.
News
New biomarker model outmatches conventional risk factors for predicting mortality
Although the majority of these biomarkers have been associated with mortality before, this is the first study that shows their independent effect...
News
FDA approves Baqsimi nasal powder for emergency hypoglycemia treatment
It is the first glucagon therapy approved for this indication that is administrable without an injection.
News
FDA issues warning on insulin pump cybersecurity weakness
The MiniMed 508 and MiniMed Paradigm series insulin pumps are being recalled because of potential cybersecurity risks; 4,000 patients in the...
Clinical
Aspirin shows little benefit for primary prevention of vascular disease in diabetes
Is aspirin for primary prevention of cardiovascular events in patients with diabetes worth the risk of adverse bleeding events?
News
SGLT2 inhibitors prevent HF hospitalization regardless of baseline LVEF
NEW ORLEANS – “At least in my mind, we have more than enough evidence at this point to say that SGLT2 inhibitors are effective in preventing heart...
Clinical
Statin exposure associated with idiopathic inflammatory myositis
What is the association between exposure to statin medications and histologically confirmed idiopathic inflammatory myositis?
News
Newer antihyperglycemic drugs have distinctive CV, kidney benefits
SGLT2 inhibitors and GLP-1 RAs have different effects on cardiovascular and kidney disease outcomes in patients with type 2 diabetes.
News
Subclinical hypothyroidism boosts immediate risk of heart failure
CHICAGO – Large Danish study links subclinical and overt hypothyroidism to immediate risk of heart failure.
News
SGLT-2 inhibitors promising for heart failure prevention, not treatment
LOS ANGELES – The combination of heart failure and diabetes is particularly lethal.